Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects who have completed previous rFVIIIFc studies (NCT01181128, NCT02083965, NCT01458106 and NCT02502149)~* Ability to understand purposes and risks of the study and to provide signed and dated informed consent (or assent, as applicable).~Key Exclusion Criteria:~* Confirmed positive high-titer inhibitor (≥5.00 BU/mL).~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: MALE
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- On-Demand (Type: EXPERIMENTAL): The individual dose of rFVIIIFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor VIII (FVIII) levels.
- Prophylaxis (Type: EXPERIMENTAL): Tailored prophylaxis, Weekly prophylaxis or Personalized prophylaxis available.

Based on this trial design, predict the completion outcome and termination type (if applicable).